Preparation of Celestone Soluspan for Knee Injection
For knee injection, withdraw 1.0 mL of Celestone Soluspan from the vial into a syringe using sterile technique; if mixing with local anesthetic, draw the Celestone first, then add 1% or 2% lidocaine without parabens, and shake briefly before injection. 1
Step-by-Step Preparation Protocol
Equipment Setup
- Use a 20- to 24-gauge needle for knee injection 1
- Ensure strict aseptic technique with surgical gloves, alcohol or chlorhexidine skin preparation 2
- Have resuscitation equipment nearby (vasovagal reactions occur in ~2.6% of cases) 2
Drawing the Medication
Withdraw Celestone Soluspan first: Draw 1.0 mL from the vial - this is the standard dose for large joints like the knee 1
If adding local anesthetic (optional but recommended for patient comfort):
- Use 1% or 2% lidocaine hydrochloride formulations without parabens 1
- Draw the lidocaine into the same syringe after the Celestone
- Shake the syringe briefly to mix 1
- Critical warning: Never inject local anesthetic back into the Celestone vial, and avoid any formulations containing methylparaben, propylparaben, or phenol as these cause flocculation (clumping) of the steroid 1
Important Technical Considerations
The 2021 EULAR guidelines emphasize that for knee injections specifically, the superolateral approach achieves 91% accuracy (95% CI 84-99%) and is the preferred entry route 2. This is the only joint where evidence supports a specific approach recommendation.
Needle changing: Change needles between drawing the medication and injecting into the joint - this reduces infection risk based on evidence from other sterile procedures 2
Injection Technique Confirmation
Before injecting Celestone:
- Insert the needle into the synovial cavity
- Aspirate a few drops of synovial fluid to confirm intra-articular placement 1
- Only then inject the prepared Celestone mixture
Critical Safety Points
Infection risk: While historically quoted at 0.005-0.0002%, recent data shows septic arthritis risk may be as high as 0.035% (3 per 7,900 procedures) 2. This makes meticulous aseptic technique non-negotiable.
Chondrotoxicity concern: Research shows that combining betamethasone with lidocaine or bupivacaine causes significant chondrotoxicity compared to local anesthetics alone 3. However, the FDA label and clinical guidelines still support this combination for patient comfort. The key is using it judiciously - the short-term benefit of pain relief during injection must be weighed against potential cartilage effects in patients requiring frequent repeat injections.
Systemic absorption: A portion of the injected dose is absorbed systemically 1. In diabetic patients, expect transient blood glucose elevation within the first hour, peaking around 322 mg/dL, lasting less than 48 hours 4. Monitor accordingly.
Duration of effect: Pain relief typically lasts approximately 3 months 5, though this varies widely between patients.